Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
CAMBRIDGE, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., today announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to six years.
- CAMBRIDGE, Mass., Jan. 10, 2024 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc., today announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to six years.
- “The data show the potential of gildeuretinol acetate to arrest Stargardt disease when treatment is started early,” said Leonide Saad, Ph.D., President and CEO of Alkeus Pharmaceuticals.
- Year-over-year progression was assessed, as well as age-matched comparison to each participant’s untreated sibling with Stargardt disease and identical mutations.
- “An efficacious and safe oral therapy that could slow or perhaps stop disease progression for this patient population would be welcomed by those living with Stargardt disease."